Previous close | 325.29 |
Open | 315.16 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 315.16 - 340.08 |
52-week range | 260.25 - 500.92 |
Volume | |
Avg. volume | 1,924 |
Market cap | 21.526B |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | 61.59 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.